NuPathe dumps Endo

Share this article:

Teva has swept in and upset Endo's NuPathe merger. Endo issued a statement Monday that NuPathe rejected Endo's bid, which meant coughing up a $5-million termination fee in order to go forward with Teva.

Specialty pharmaceutical company Endo offered $104 million for the company, but Business Week says Teva topped this by offering $144 million.

The deal means NuPathe's Zecuity migraine patch will now belong to Teva.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.